<DOC>
	<DOCNO>NCT02034227</DOCNO>
	<brief_summary>The purpose study determine experimental drug , SG2000 safe tolerable treatment participant advance chronic lymphocytic leukemia acute myeloid leukemia whose standard treatment work , whose cancer come back candidate type standard therapy .</brief_summary>
	<brief_title>Safety , Tolerability Study SG2000 Treatment Advanced Chronic Lymphocytic Leukemia Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>male female great equal 18 year age one follow disease state : Acute Myeloid Leukemia ( AML ) ( age &lt; 60 year ) relapsed/refractory disease ; •Chronic Lymphocytic Leukemia ( CLL ) relapse disease follow fludarabinebased regimen relapse disease follow alkylatorbased regimen recover acute adverse effect prior therapy ( exclude alopecia Grade ≤2 neuropathy ) . blast count control use hydroxycarbamide ( 500 3000 mg daily ) . adequate hepatic function renal function estimate life expectancy &gt; 3 month female subject must negative serum pregnancy result within 7 day start study ; Both men woman must agree use medically acceptable form contraception throughout treatment period 3 month discontinuation treatment eligible standard therapy know life prolong life save diagnosis AML FrenchAmericanBritish ( FAB ) classification ( FAB ) M3 ( acute promyelocytic leukemia ( APL ) ) receive concurrent chemotherapy , radiotherapy , immunotherapy , biological hormonal treatment cancer . undergone anticancer therapy include chemotherapy ( except hydroxycarbamide maximum daily dose 3000 mg ) , endocrine therapy , immunotherapy , use investigational agent within 4 week study entry . prior radiation therapy volume bone marrow treat 25 % . use immunosuppressive therapy , include systemic steroid within 7 day first dose SG2000 . hyperleukocytosis ( blast count &gt; 30 000/mm3 ) . history allogeneic stem cell solid organ transplantation . positive serology human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C HIVAIDS , active hepatitis B C. history invasive malignancy within 3 year except cervical carcinoma situ , nonmelanomatous carcinoma skin ductal carcinoma situ breast surgically cure . coexist medical condition substantially increase risk associate subject 's participation study . psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study . persistent Grade 2 great toxicity cause ( except alopecia peripheral neuropathy ) . pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>leukemia</keyword>
</DOC>